Shanghai Microport Endovascular Medtech (Group) Co., Ltd. (688016.SH), a subsidiary of MICROPORT (00853), has released its preliminary annual results for 2025. The company reported total operating revenue of approximately 1.351 billion yuan, an increase of 11.96% year-on-year. Net profit attributable to owners of the parent company was about 563 million yuan, rising 12.17% compared to the previous year. Basic earnings per share were 4.65 yuan.
During the reporting period, the company's innovative products strengthened their leading domestic position. Through strategies such as penetrating lower-tier markets, offering customized treatment solutions, and upgrading products, the company accelerated the promotion of new items and the replacement of older ones, steadily increasing its market share. However, due to the lingering effects of market price regulations from 2024 and adjustments to the pricing and promotion strategies for some products, the full-year growth rates for both sales revenue and profit were somewhat impacted.
Overseas sales revenue for the period exceeded 250 million yuan, growing more than 55% year-on-year, and now accounts for over 18% of the company's total revenue. The company continued to advance collaborations with leading regional clients globally and furthered market access and promotion efforts for its aortic and peripheral vascular intervention products in Europe, Latin America, Asia-Pacific, and other regions. By the end of the reporting period, the company's products were available in 49 countries and territories, including China.
Several new innovative products were approved for launch in China, including the Cratos branched aortic stent-graft system, a transjugular intrahepatic puncture kit, and polyvinyl alcohol embolization microspheres. Cumulatively, 23 of the company's products have received their first registration certificates from the NMPA, while 11 products have obtained initial registration approvals in 28 overseas markets. The company has secured more than 110 overseas product registrations in total, including CE marking for 6 products and EU custom-made certification for 3 products.
Beyond these products, the company's R&D pipeline progressed steadily. The Aegis II abdominal aortic stent-graft system has completed its registration document submission. The Hector multi-branch thoracic aortic stent-graft system has entered the pre-market multi-center clinical trial stage in China and was included in the national innovation "green channel" during the reporting period. It has already been commercialized in the EU under a custom-made pathway, and an application for Breakthrough Device Designation has been submitted to the U.S. FDA. The thoracoabdominal aortic stent-graft system (custom-made) has received a domestic filing certificate. The iliac artery branch stent-graft system is preparing to enter the clinical trial initiation phase.
For the peripheral vascular business, several products, including a peripheral intervention microcatheter, detachable fibered embolization coil, mechanical thrombectomy catheter, and a new-generation peripheral plain balloon catheter, are expected to receive approval for market launch in 2026. The below-the-knee drug-coated balloon catheter and the TIPS stent-graft system have completed registration submissions. The peripheral vascular drug-eluting stent system is currently in the clinical implantation stage.
Concurrently, the company is pursuing overseas registrations (including CE, FDA, etc.) for its innovative products. The company aims to continuously enhance its competitiveness in the aortic and peripheral vascular intervention markets and maintain a rapid growth trajectory.
Comments